Cell therapy manufacturing services provider
See open opportunities
To enable the cost-effective parallel production of thousands of cell therapy doses per month.
The East Side, South San Francisco, CA
Some candidates hear
back within 2 weeks
44% employee growth in 12 months
CTO of Otta
Cellares has adopted an innovative role in the automation of cell therapy manufacturing. Cellares argues that the potential of cell therapy is limited by manufacturing bottlenecks, and so its scalable solution makes a huge contribution to this space.
The company's manufacturing system, the Cell Shuttle, is set to be the solution needed to ensure that cell therapy isn't held back by disjointed, cost-prohibitive, and failure-prone procedures. This "factory in a box" houses the instruments needed to handle cells and turn them into therapies and could be market ready by 2024.
The potential for expansion in this niche is massive, as only 10% of the required manufacturing capacity for this field exists today. Cellares is therefore tapping into this market with a robust, cost-effective solution. Its automation, flexibility, and scalability will be hugely valuable to many businesses. Since the automation of systems in this field can result in a 70% cost reduction, this gives the company a competitive edge in a sector that is set to heat up soon.
Last 2 fundraises
This company has top investors
Electrical Engineering at San Jose State. Engineer at Thermo Fisher Scientific and Finesse Solutions, before becoming VP at Finesse then Synthego. Co-founded Cellares in 2019.
Masters Degree in Aerospace Engineering at University of Munich. Chief Innovation Officer at Synthego, before co-founding Cellares in 2019.
Claim your profile to receive high quality applications from relevant candidates.Claim profile
For job seekers
Sign in or sign up to discover relevant roles at exciting companies.Sign in or sign up
Cellares is hiring for 6 jobs on Otta!
Finance, Legal & Compliance